ABSTRACT
INTRODUCTION
Prostate cancer (PC) is the most common cancer in men in the United States, and the second leading cause of cancer death among males. 1 The American Cancer Society (ACS) estimates that approximately 181,000 new cases of PC will be diagnosed in 2016, with mortality at less than 27,000. 2 This means approximately 1 in 7 men will be diagnosed with PC during their lifetime, and most are living many years after the diagnosis. The relative 5-year survival rate in the United States is almost 100% for all stages of PC, while the 10-year and 15-year survival rates are 99% and 94%; respectively. 3 According to ACS, more than 2.9 million men in the United States diagnosed with PC are still living as of January of 2016. 2 As the number of men surviving prostate cancer (PCS) continues to grow, research has demonstrated that many PCS will have significant impairments of body structures and function. 3 These impairments often go undetected and/or untreated, and consequently may result in frailty. 3 Men treated for prostate cancer will experience a decrease in lean muscle mass and strength during the first year of androgen deprivation therapy (ADT) with an estimated 50% of PCS receiving this treatment in the early stages. 4 A typical course of ADT treatment may last anywhere from 2-3 years. During the first year of ADT, PCS will experience a deficiency in sex hormones, insulin resistance, increased central/visceral adiposity, decreased bone density, decreased lean muscle mass and whole body muscle strength. 4 Adverse changes in muscle composition may exacerbate normal sarcopenia, further reducing muscular strength and endurance as well as functional mobility and independence. 5 A study of older PCS (mean age 69 years) found that these men are at a greater risk for other comorbid conditions and physical limitations (for example, cardiovascular disease, diabetes, osteoporosis, skeletal fractures, impaired balance and falls) that may dramatically affect their muscle performance and physical function. 6 Evidence of the impact of ADT and cancer treatments on PCS is consistently strong in terms of a detrimental effect on functional abilities. In a recent study of PCS post-treatment, 24% had impairments in activities of daily living (ADLs), 42% had impairment in instrumental activities of daily living (IADLs), 56% had abnormal Short Physical Performance Battery (SPPB) findings, and 22% reported falls within the previous three months. 4 Within the SPPB, deficits occurred within all subcomponents (balance, walking, and chair stands). Using a univariate analysis, age, deficits in ADLs and IADLs, and abnormal cognitive and functional screen findings were associated with an increased risk of decreased physical performance for PCS. 6 When compared to age-matched healthy controls, survivors had a slower walking speed, poorer physical performance and lower levels of patient-reported physical function. Decreased gait speed is associated with mobility limitations, disability, and increased mortality. Deficits in ADLs, the use of an assistive device, and abnormal functional screening findings were associated with an increased risk of falling. 6 Falls may lead to more serious injuries such as an increased risk of fractures and hospitalizations, thereby decreasing the quality of life and level of independence for survivors. In summary, the multitude of physiological changes resulting from ADT treatment of prostate cancer profoundly impacts the functional mobility of these men. It is therefore essential to measure functional mobility in order to identify deficits, risks for further injury such as falls, and design and assess the effectiveness of appropriate treatment regimens.
In 1991, the Task Force on Standards for Measurement in Physical Therapy of the American Physical Therapy Association (APTA) established the criteria for valid, reliable, objective, and standardized tests and measures to assist clinicians in providing the highest quality Effectiveness (EDGE) Task Force was developed to address these barriers in the physical therapy profession.
In 2010, the APTA's Oncology Section created an EDGE Task Force to develop recommendations for outcome measures used when assessing the status of cancer survivors.
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The reliability, validity, minimal detectable change (MDC) and/or minimal clinically important difference (MCID) are important psychometric properties which need to be evaluated to justify clinical use of outcome measures. 8 Additionally, tools used to track and measure patient outcomes should be validated in the population in which they are used to be most beneficial.
Lastly, these tools need to be evaluated in light of clinical utility, including the availability of resources, cost, ease of use, and availability of normative data. To date, Oncology EDGE Task
Forces have reviewed quality of life measures and measures of strength and muscular endurance for the prostate cancer population. 12, 13 These reviews are in addition to 13 reviews completed for the breast cancer population, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] four reviews completed for the head and neck cancer population, 27-30 and one review for the colorectal cancer population. 31 The purpose of this systematic review is to make recommendations of the best methods to evaluate functional mobility in PCS based on psychometric properties and clinical utility.
METHODS

Search Strategy
The authors systematically assessed the literature for outcome measures that either directly measured or utilized patient self-report to evaluate functional mobility with the express purpose of evaluating the psychometric properties and clinical utility of these measures for patients with prostate cancer. 
Data Extraction and Analysis
Each outcome measure was appraised by two reviewers independently using the Cancer EDGE Outcome measures were then rated 1-4 (lowest to highest recommendation) on the Cancer EDGE Rating Scale, taking into consideration both psychometric qualities and clinical utility (see Figure 1) . If the two reviewers agreed on the rating of the outcome measure, the rating stood. If an outcome measure rating was found to be in disagreement between the two independent reviewers, the disagreement was resolved by discussion with all five reviewers until agreement was obtained. Finally, all articles reviewed for an outcome measure were included in a reference section of the EDGE form for each appropriate measure.
RESULTS
The initial literature search of electronic databases and bibliographic review for functional mobility assessments of those treated for prostate cancer resulted in 38,373 articles including duplicates. After title and abstract review, and removal of duplicates, 248 articles were retrieved and assessed for eligibility. A total of 152 articles met inclusion criteria and were included in the final review. Figure 2 delineates the flow of the literature search. 
DISCUSSION
The purpose of this systematic review is to make recommendations of the best methods to evaluate functional mobility in PCS based on psychometric properties and clinical utility. Men treated for PC with ADT are known to have reduced lower body strength by 22% and decreased bone density compared to healthy controls; 5,34-36 combined with increased age, this combination sets-up increased risk for falling with functional activities such as rising from a chair, dynamic balance activities such as reaching, and slowing gait speed with ambulation. 36 It is important to assess walking, balance and functional ability in the home and community environments during the initial examination to determine the presence of physical impairments, functional deficits and activity limitations, and participation restrictions, in order to identify the impact of cancer treatment on the individual's overall function, including fall risk.
Within the ICF, functional mobility is included in the mobility domain, and intersects with ADLs and participation within environment and life situation contexts. This review includes multiple measures of walking, ADLs, and self-reported community function. The seven highly recommended (rating of 4) and three recommended (rating of 3) measures are discussed; the remaining measures reviewed that lack either psychometric support or clinical utility are not recommended for use by the EDGE Task Force. Included highly recommended measures are: 2-MWT and 6-MWT, the 10-meter timed walk, the (TUG), the 5xSTS, the SPPB, and the PPB.
Recommended measures include the LIFE-H, the FIM and the AM-PAC. Most of the recommended measures, seven, are from the walk test category while three are from the ADL category.
Walk Tests
The ability to walk safely and competently is essential for an individual to move around the environment. The 2MWT and 6MWT involve the individual walking as far as they can in 2 or 6 minutes respectively. A participant may rest at any time and use a walking aid as needed.
These tests demonstrated good-excellent reliability in older adults, neurological populations and The 5xSTS is also highly recommended. This test involves rising from a standard chair 5 times as fast as possible, with arms folded across the chest, and is focused on transitional movements and lower extremity strength. 74 The time to complete the test is recorded in seconds.
This test is easy to administer in the clinic and is reliable in older female adults (ICC=0.95).
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The 5xSTS was validated with the 6-MWT 42 and the TUG. 75 The MDC in older female adults is 2.5 seconds. 75 Additionally, this test was used in research on the prostate cancer population. 50, 76, 77 This test incorporates assessment of both transitional movement and a functional measure of lower extremity strength making this a useful clinical tool.
Two functional performance batteries, the Short Performance Physical Battery (SPPB), and the Physical Performance Battery for Patients with Cancer (PPB), are highly recommended by the EDGE Task Force. The SPPB is a collection of physical tests that determine function in activities of daily living. The SPPB is easy to administer and involves walking at a normal pace, a balance task, and incorporates the 5xSTS. 78 The design of the test makes it relatively easy to administer in a clinical setting, and seeks to quantify physical performance on a number of simple skills required for functional mobility. 78 Reliability is good (ICC=0.83-0.89) [79] [80] [81] [82] and it is validated with self-reported mobility and ADL with associated disability. 78 The MDC in the elderly population is 1. 
Activity of Daily Living Functional Tests
Three ADL functional tests are given a rating of 3, recommended, the highest rating given by the EDGE Task Force in this category. They are the LIFE-H, the FIM, and the AM-PAC. The LIFE-H has a long and short form, covering 12 domains, with the number of items being 240 and 69 respectively. [89] [90] [91] [92] [93] The domains include: personal care, interpersonal relationships, nutrition, community life, recreation and mobility, with the intent to assess the perception of one's ability to participate socially. The scoring is complex and the time to administer the test (one hour for the short form and two hours for the long form) may impact its clinical utility. However, sound psychometric properties and the comprehensive nature of the test warrant the investment of time. The validity of the LIFE-H has not been reported in a cancer population.
The FIM contains 18 items comprised of 5 cognitive and 13 motor tasks. The FIM is used to assess quality of life in persons with a disability and the need for assistance to complete activities within the individual's environment. 94 The FIM has good psychometric properties, [95] [96] [97] [98] however the FIM's clinical utility may be restrictive as the FIM has a cost associated with use, takes 30 -40 minutes to administer, and is scored via consensus with other health care providers.
Also, therapists need to be trained to utilize the tool. Despite these barriers to implementation, the EDGE Task Force recommends this tool because of the comprehensive nature of the assessment, which provides the clinician with a clear picture of the impact of function on quality of life and daily activity. Use of the FIM has not been reported in the prostate cancer population.
The AM-PAC was developed to assess functional status of all individuals across the continuum of care. 99 Based on ICF domains, the AM-PAC is a self-report 41-item comprehensive scale to test physical and movement activity (10 items), personal care and instrumental activity (16 items), and applied cognitive activity (15 items 
Self-Reported Community Participation Measures
No measures in this category are recommended due to poor psychometric properties, poor clinical utility, and lack of evidence of use in a cancer population. The IPAQ, the LISAT-9
Modified Rankin Scale, and the POPS are all rated 2B. The PARTS-M, HiMAT, FSE, and
Reintegration to Normal Living/Life Index are all not recommended by the Task Force.
Limitations and Future Research
Evidence based practice requires that the best evidence available is utilized in clinical Task Force recommendations are made with the best available evidence at the time, but in using these measures, the reader is encouraged to continue to use best judgement in applying these recommendations to the individual patient.
Clearly, additional research is needed in validating all of these measures in the prostate cancer population. Studies examining reliability and responsiveness to change of these measures in men treated for prostate cancer is a significant gap in the evidence database. More studies utilizing these measure as outcomes need to be developed. Perhaps most importantly, better measures of assessing functional mobility within the context of community participation need to be developed.
Conclusion
In patients with prostate cancer, with or without ADT, the assessment of functional mobility is important to assess impairment, functional deficits, activity limitations, and participation restrictions. Multiple assessment tools exist to assess walking and ADLs, however, limited research in Self-Reported Community Participation tools render them inadequate at this time. Seven tests are highly recommended by the Oncology EDGE Task Force; 2-and 6-MWT, 10-meter timed walk, the TUG, the 5xSTS, the SPPB, and the PPB, based on good clinical utility and psychometric properties. Three tests are recommended but lack use in the cancer population: 
Highly Recommend
The outcome has good psychometric properties and good clinical utility; the measure has been used in research on individuals with or post cancer.
Recommend
The outcome measure has good psychometric properties and good clinical utility; no published evidence that the measure has been applied to research on individuals with or post cancer.
2A
Unable to Recommend at this time
There is insufficient information to support a recommendation of this outcome measure; the measure has been used in research on individuals with or post cancer.
2B
Unable to Recommend at this time
There is insufficient information to support a recommendation of this outcome measure; no published evidence that the measure has been applied to research on individuals with or post cancer. 
